These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18550412)

  • 21. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohn's disease.
    Iizuka M; Sagara S; Etou T
    Inflamm Bowel Dis; 2011 Jul; 17(7):E67-8. PubMed ID: 21509909
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adalimumab in Crohn's disease - data from real life].
    López San Román A; Van Domselaar M; Garrido E
    Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
    [No Abstract]   [Full Text] [Related]  

  • 25. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease.
    Umeno J; Matsumoto T; Jo Y; Ichikawa M; Urabe K; Iida M
    Inflamm Bowel Dis; 2007 Sep; 13(9):1188-9. PubMed ID: 17427237
    [No Abstract]   [Full Text] [Related]  

  • 26. [Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?].
    Bode M; Eder S; Schürmann G
    Z Gastroenterol; 2008 Dec; 46(12):1376-83. PubMed ID: 19053007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crohn's disease in common variable immunodeficiency: treatment with antitumor necrosis factor alpha.
    Nos P; Bastida G; Beltran B; Aguas M; Ponce J
    Am J Gastroenterol; 2006 Sep; 101(9):2165-6. PubMed ID: 16968516
    [No Abstract]   [Full Text] [Related]  

  • 28. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
    Sorrentino D; Terrosu G; Vadalà S; Avellini C
    Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
    [No Abstract]   [Full Text] [Related]  

  • 29. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease.
    Ferkolj I; Hocevar A; Golouh R; Dolenc Voljc M
    Acta Dermatovenerol Alp Pannonica Adriat; 2006 Dec; 15(4):173-7. PubMed ID: 17982610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation].
    Jung BY; Lee SH; Chung SK; Lee CK; Lee TH; Chung IK; Kim SJ; Cho HD
    Korean J Gastroenterol; 2012 Jun; 59(6):437-40. PubMed ID: 22735878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab in fistulizing Crohn's disease.
    Osterman MT; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rheumatic fever in a patient receiving infliximab therapy for Crohn disease.
    Abu-El-Haija M; Stasheff S; Atkins DL; Bishop WP
    J Pediatr Gastroenterol Nutr; 2011 Mar; 52(3):360-1. PubMed ID: 21150656
    [No Abstract]   [Full Text] [Related]  

  • 33. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
    Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
    Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crohn's disease in a child: unusual presentation with severe osteoporosis.
    Ferreira R; Almeida S
    BioDrugs; 2010 Dec; 24 Suppl 1():31-3. PubMed ID: 21175234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab.
    Carpenter E; Jackson MA; Friesen CA; Scarbrough M; Roberts CC
    J Pediatr; 2004 Apr; 144(4):541-4. PubMed ID: 15069408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regression of Sweet's syndrome associated with Crohn's disease after anti-Tumour Necrosis Factor therapy.
    Rahier JF; Lion L; Dewit O; Lambert M
    Acta Gastroenterol Belg; 2005; 68(3):376-9. PubMed ID: 16268426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-TNF therapy and Crohn's disease].
    Peyrin-Biroulet L
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):478-81. PubMed ID: 18439777
    [No Abstract]   [Full Text] [Related]  

  • 40. Esophageal ulcer of Crohn's disease: disappearance in 1 week with infliximab.
    Chiba M; Sugawara T; Tsuda H; Abe T; Tokairin T; Kashima Y
    Inflamm Bowel Dis; 2009 Aug; 15(8):1121-2. PubMed ID: 18942761
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.